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osting by EAbstract Twenty-seven years old healthy woman presented with complaints of sudden painless
blurred vision in right eye for 1 week. On examination, visual acuity was 20/30 in the right eye
and 20/20 in left eye. Fundus examination OS was normal; OD demonstrated a ﬂat, opaque, yel-
lowish parapapillary choroidal lesion with grayish membrane associated with minimal subretinal
ﬂuid suggestive of a CNVM in the center. B-scan ultrasonography revealed ﬁndings consistent with
a choroidal osteoma. Fundus ﬂuorescein angiography of the right eye revealed a relatively well-
deﬁned area of hyperﬂuorescence that increased in size and intensity in the later phases suggestive
of active extrafoveal CNVM. Optical coherence tomography conﬁrmed the extrafoveal CNVM
with subfoveal ﬂuid. She was treated with intravitreal Bevacizumab OD. At the 2 weeks visit, vision
OD improved to 20/20. The FFA and OCT revealed a resolved CNVM. Intravitreal Bevacizumab
may be an effective alternative in the management of CNVM secondary to choroidal osteoma.
ª 2010 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.M. Joshi Eye Institute, Room
dia. Tel.: +0836 2228431/32/
2375933.
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lsevier1. Introduction
The term choroidal osteoma was coined by Gass in 1978 when
he described four healthy young women with characteristic
ophthalmoscopic ﬁndings of slightly elevated, yellowish, juxta-
papillary, choroidal tumour with sharp geographic borders
(Gass et al., 1978). These tumours demonstrate evidence of
bone formation in the choroid and are believed to be chorist-
omatous in origin (Aylward et al., 1998). The majority of pa-
tients with choroidal osteoma maintain good vision. In a
follow-up study of 36 patients, the probability of loss of visual
acuity (20/200 or worse) was more than 50% by 10 years
(Shields et al., 1988). Choroidal neovascularization is the most
200 G.S. Ayachit et al.frequent cause of visual loss in choroidal osteoma with more
than half of the patients expected to develop choroidal neovas-
cularization (Aylward et al., 1998; Kadrmas and Weiter, 1997).
2. Case history
Twenty-seven years old female came with the chief complaint
of blurred vision in right eye for 1 week. Her past ocular,
medical and family histories were non-contributory. On
examination her best corrected visual acuity was 20/30 N6 in
right eye and 20/20 N6 in left eye. Her intraocular pressure
was 11 mm Hg in right eye and 13 mm Hg in left eye. Her ante-Figure 1 FFA and OCT showing corresponding locat
Figure 2 FFA of right eye showing early lacy hyperﬂuorescence o
shadowing due to osteoma.rior segment examination in both eyes and fundus examination
of left eye were unremarkable. Ophthalmoscopic examination
in right eye showed a yellowish lesion on posterior pole of
about 5 mm · 5 mm in size (Fig. 1). It was smooth on the sur-
face with slight elevation. In the center of the lesion, subretinal
hemorrhage of a ﬁne dot size was noted. On fundus ﬂuorescein
angiography, it showed early patchy hyperﬂuorescence with
late staining of the lesion. In the center of the lesion and about
1 disc diameter nasal to FAZ early lacy hyperﬂuorescence
(Fig. 2) which was leaking in the late phase, was noted indica-
tive of classic choroidal neovascular membrane while left eye
showed an angiogram within normal limits. There was alsoion of CNVM associated with osteoma in right eye.
f CNVM with later leakage and B scan showing corresponding
Figure 4 FFA showing regressed CNVM with no leakage (early, mid and late phase in clockwise).
Figure 3 Absence of subfoveal ﬂuid on OCT with regressed CNVM.
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rhage seen clinically. B scan showed very high reﬂectivity on
surface with shadowing behind because of presence of calcium
in the lesion (Fig. 2). Optical coherence tomography conﬁrmed
choroidal neovascular complex with subretinal ﬂuid extending
to fovea (Fig. 1). A diagnosis of osteoma with choroidal neo-
vascular membrane was made. She underwent intravitreal Bev-
cizumab injection for the choroidal neovascular membrane. It
showed regression at 1 week follow up with resolution of
subretinal hemorrhage and no ﬂuid on OCT (Fig. 3) and no
leakage on ﬂuorescein angiography (Fig. 4). The lesion re-
mained stable at monthly follow up even at 6 months with ﬁnal
visual acuity of 20/20 N6 at the last visit.
3. Discussion
Owing to lack of pigment in the tumour and atrophy of over-
lying retinal pigment epithelium, laser photocoagulation has
limited efﬁcacy (25%) in the treatment of choroidal neovascu-
larization secondary to choroidal osteoma. Intravitreal Bev-
acizumab (IVB) is independent of the intrinsic pigmentation
and has the advantage of sparing overlying retina. So despite
having extrafoveal CNVM, we preferred IVB over laser.Encouraged by the results of the AntiVEGFs for choroidal
neovascular membranes in choroidal osteomas by Ahmadieh
and Vaﬁ (2007) and Narayanan and Shah (2008) we performed
intravitreal Bevacizumab and achieved complete regression of
choroidal neovascularization. Since the visual acuity was 20/30
with minimal subfoveal ﬂuid and there was concern regarding
the possibility of extension of the choroidal neovascular mem-
brane into the foveal region, we kept a close follow up during
the regression period. There are case reports with treatment of
CNVM associated with choroidal osteomas with photody-
namic therapy and ranibizumab with good efﬁcacy, but cost
effectiveness is a constraint (Shields et al., 2008; Song and
Roh, 2009). Our case illustrates that choroidal neovasculariza-
tion secondary to a choroidal osteoma can be successfully trea-
ted with IVB which is very cost effective as compared to other
modalities of treatment.
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